Article
KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex.
PloS one - 1 Jan 2018
Rao Donald D, Luo Xiuquan, Wang Zhaohui, Jay Christopher M, Brunicardi Francis C, Maltese William, Manning Luisa, Senzer Neil, Nemunaitis John
Abstract excerpt
The KRAS oncogene, present in over 90% of pancreatic ductal adenocarcinomas, is most frequently the result of one of three gain-of-function substitution mutations of codon 12 glycine. Thus far, RAS mutations have been clinically refractory to both direct and selective inhibition by systemic therapeutics. This report presents the results of pre-clinical assessment of a lipoplex comprising a plasmid-encoded,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.